T

Tarsus Pharmaceuticals
D

TARS

72.080
USD
1.62
(2.30%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
44,855
الربح لكل سهم
-7
العائد الربحي
-
P/E
-67
حجم السوق
3,372,744,871

العنوان: Tarsus Pharmaceuticals

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.